Wu Licun, Zhang Chengke, Zhao Xiaogang
Latner Thoracic Surgery Research Laboratories and Division of Thoracic Surgery, Toronto General Hospital, University Health Network, University of Toronto, Princess Margaret Cancer Research Tower, Toronto, ON, M5G 2C4, Canada.
Key Laboratory of Thoracic Cancer, Cheeloo College of Medicine, Shandong University, Ji'nan 250033, Shandong Province, China.
World J Oncol. 2021 Feb;12(1):1-6. doi: 10.14740/wjon1367. Epub 2021 Feb 24.
Since the outbreak of 2019 novel coronavirus disease (COVID-19) induced by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pandemic has become a global catastrophe. Patients with cancer especially lung cancer are more vulnerable and susceptible to get infected by the virus SARS-CoV-2. The overwhelming impact of COVID-19 on lung cancer community may result in rise of the incidence and mortality of lung cancer. It would become more obvious in future retrospective studies. Lung cancer patients are believed at higher risk of COVID-19 due to immunosuppression and should be protected by vaccination with priority. Better understanding of SARS-CoV-2 could help develop more effective vaccines to eradicate this disease in the near future.
自严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引发2019新型冠状病毒病（COVID-19）疫情以来，这场大流行已成为一场全球灾难。癌症患者尤其是肺癌患者更容易受到SARS-CoV-2病毒感染。COVID-19对肺癌群体的巨大影响可能导致肺癌发病率和死亡率上升。这在未来的回顾性研究中将变得更加明显。由于免疫抑制，肺癌患者被认为感染COVID-19的风险更高，应优先通过接种疫苗进行保护。更好地了解SARS-CoV-2有助于在不久的将来研发出更有效的疫苗来根除这种疾病。
